GE Healthcare Forms Biomolecular Imaging Alliance with Fujifilm
|
By MedImaging International staff writers Posted on 17 Jun 2009 |
GE Healthcare (Chalfont St. Giles, UK), a unit of General Electric Co. (Fairfield, CT, USA), has entered into a strategic alliance agreement with Fujifilm Corp. (Tokyo, Japan). Under the terms of alliance, Fujifilm will develop, manufacture, and supply advanced biomolecular-imaging systems to GE Healthcare. The products will be sold worldwide under the GE brand in the life science research and drug discovery markets.
Life science research has advanced rapidly in recent years with the advent of tools for genomic and protein research such as biomolecular labeling, detection, and analysis. These technologies have helped reveal the functions of proteins, thereby contributing to scientists' understanding of disease processes. The use of life science instrumentation and reagents in bioscience research is growing, and the demand for new and innovative enabling technologies is expanding.
In 1987, Fujifilm was the first company to introduce the innovative digital autoradiography device, which utilized the imaging plate, a radiation detector with sensitivity 100 times greater than X-ray film. Since then, Fujifilm has utilized its chemical and optical technologies cultivated in the field of photo imaging to launch a wide range of instruments, including innovative charged coupled device (CCD) camera systems, contributing to the advancement of imaging in genomic and protein research.
In 1923, GE Healthcare introduced the first radioisotope reagents, which initiated the field of biomolecular labeling and detection. Since then, GE Healthcare has introduced a series of nonradioactive detection reagents, such as ECL and CyDyes, to enable safe and quantitative biomolecular labeling, detection, and analysis. The company's system solutions have radically improved the way scientists can analyze gene and protein expression in tissues and cells.
"This deal represents an important progression for our business,” stated Yuzo Toda, director, corporate vice president, general manager of life science products division, Fujifilm. "By forming the alliance, both companies will make the most of our complementary capabilities to continue to contribute to the advancement of genomic and protein research, and to help enhance the quality of life of people worldwide. GE Healthcare's global presence as a supplier of reagents and instruments, and its competence in biological applications within the life science field combined with Fujifilm's leading imaging technologies, R&D and manufacturing capabilities will provide our customers with comprehensive system solutions for research, drug discovery and bioanalytical applications.”
"We are delighted to work with Fujifilm to expand our support to bioscience research in biomolecular imaging system solutions,” said Nigel Darby, general manager of biotechnologies, life sciences, GE Healthcare. "Fujifilm‘s high-quality technology platforms fit well with our proprietary labeling technologies and the adjacent fields in the imaging workflow that GE Healthcare currently addresses. Furthermore, the integration of the imaging platform with our global service organization will give strong and valuable customer support.”
Fujifilm will supply image-analyzing systems for bioscience research to GE Healthcare, and GE Healthcare will market and sell them under the GE brand. GE Healthcare will be responsible for marketing/sales of the systems worldwide, and will provide total solutions including instruments, electrochemiluminescence (ECL) and differential in-gel electrophoresis (DIGE) labeling reagents, and applications support. Additionally, GE Healthcare will provide instrument services for the systems. Lastly, Fujifilm and GE Healthcare will collaborate to develop image-analyzing systems that are optimized for customer applications.
GE Healthcare provides transformational medical technologies and services for patient care. The company's expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help in delivering better care to more people worldwide.
Fujifilm is one of the major operating companies of Fujifilm Holdings. The company is now applying these their expertise in film technologies to the prevention, diagnosis, and treatment of diseases in the medical and life science fields. Fujifilm is also expanding growth in the highly functional materials business, including flat panel display materials, and in the graphic systems and optical devices businesses.
Related Links:
GE Healthcare
Fujifilm
Life science research has advanced rapidly in recent years with the advent of tools for genomic and protein research such as biomolecular labeling, detection, and analysis. These technologies have helped reveal the functions of proteins, thereby contributing to scientists' understanding of disease processes. The use of life science instrumentation and reagents in bioscience research is growing, and the demand for new and innovative enabling technologies is expanding.
In 1987, Fujifilm was the first company to introduce the innovative digital autoradiography device, which utilized the imaging plate, a radiation detector with sensitivity 100 times greater than X-ray film. Since then, Fujifilm has utilized its chemical and optical technologies cultivated in the field of photo imaging to launch a wide range of instruments, including innovative charged coupled device (CCD) camera systems, contributing to the advancement of imaging in genomic and protein research.
In 1923, GE Healthcare introduced the first radioisotope reagents, which initiated the field of biomolecular labeling and detection. Since then, GE Healthcare has introduced a series of nonradioactive detection reagents, such as ECL and CyDyes, to enable safe and quantitative biomolecular labeling, detection, and analysis. The company's system solutions have radically improved the way scientists can analyze gene and protein expression in tissues and cells.
"This deal represents an important progression for our business,” stated Yuzo Toda, director, corporate vice president, general manager of life science products division, Fujifilm. "By forming the alliance, both companies will make the most of our complementary capabilities to continue to contribute to the advancement of genomic and protein research, and to help enhance the quality of life of people worldwide. GE Healthcare's global presence as a supplier of reagents and instruments, and its competence in biological applications within the life science field combined with Fujifilm's leading imaging technologies, R&D and manufacturing capabilities will provide our customers with comprehensive system solutions for research, drug discovery and bioanalytical applications.”
"We are delighted to work with Fujifilm to expand our support to bioscience research in biomolecular imaging system solutions,” said Nigel Darby, general manager of biotechnologies, life sciences, GE Healthcare. "Fujifilm‘s high-quality technology platforms fit well with our proprietary labeling technologies and the adjacent fields in the imaging workflow that GE Healthcare currently addresses. Furthermore, the integration of the imaging platform with our global service organization will give strong and valuable customer support.”
Fujifilm will supply image-analyzing systems for bioscience research to GE Healthcare, and GE Healthcare will market and sell them under the GE brand. GE Healthcare will be responsible for marketing/sales of the systems worldwide, and will provide total solutions including instruments, electrochemiluminescence (ECL) and differential in-gel electrophoresis (DIGE) labeling reagents, and applications support. Additionally, GE Healthcare will provide instrument services for the systems. Lastly, Fujifilm and GE Healthcare will collaborate to develop image-analyzing systems that are optimized for customer applications.
GE Healthcare provides transformational medical technologies and services for patient care. The company's expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help in delivering better care to more people worldwide.
Fujifilm is one of the major operating companies of Fujifilm Holdings. The company is now applying these their expertise in film technologies to the prevention, diagnosis, and treatment of diseases in the medical and life science fields. Fujifilm is also expanding growth in the highly functional materials business, including flat panel display materials, and in the graphic systems and optical devices businesses.
Related Links:
GE Healthcare
Fujifilm
Latest Industry News News
- GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026
- GE HealthCare Highlights AI-Supported Radiation Therapy Tools at ESTRO 2026
- Nuclear Medicine Set for Continued Growth Driven by Demand for Precision Diagnostics
- GE HealthCare and NVIDIA Collaboration to Reimagine Diagnostic Imaging
- Patient-Specific 3D-Printed Phantoms Transform CT Imaging
- Siemens and Sectra Collaborate on Enhancing Radiology Workflows
- Bracco Diagnostics and ColoWatch Partner to Expand Availability CRC Screening Tests Using Virtual Colonoscopy
- Mindray Partners with TeleRay to Streamline Ultrasound Delivery
- Philips and Medtronic Partner on Stroke Care
- Siemens and Medtronic Enter into Global Partnership for Advancing Spine Care Imaging Technologies
- RSNA 2024 Technical Exhibits to Showcase Latest Advances in Radiology
- Bracco Collaborates with Arrayus on Microbubble-Assisted Focused Ultrasound Therapy for Pancreatic Cancer
- Innovative Collaboration to Enhance Ischemic Stroke Detection and Elevate Standards in Diagnostic Imaging
- RSNA 2024 Registration Opens
- Microsoft collaborates with Leading Academic Medical Systems to Advance AI in Medical Imaging
- GE HealthCare Acquires Intelligent Ultrasound Group’s Clinical Artificial Intelligence Business
Channels
Radiography
view channel
Rapid X-Ray Test Quantifies Pulmonary Regurgitation After Tetralogy of Fallot Repair
Tetralogy of Fallot is the most common cyanotic congenital heart defect and can leave patients with pulmonary valve regurgitation, a backward flow of blood into the right ventricle after repair.... Read more
AI Tool Flags Osteoporosis Risk from Routine Chest X-Rays
Osteoporosis is a progressive loss of bone density that is often silent until a fracture occurs. Current screening frameworks concentrate on older women and select high-risk groups. Many men, younger adults,... Read moreMRI
view channel
AI Approach Could Shorten Advanced Brain MRI Scans by Up to 90%
Long acquisition times for advanced brain magnetic resonance imaging (MRI) can limit access, extend waiting lists, and disrupt clinical workflows. Reducing data requirements without sacrificing image fidelity... Read more
Cardiac MRI Measure Improves Risk Prediction in Tricuspid Regurgitation
Tricuspid regurgitation, in which blood flows back from the right ventricle into the right atrium, can lead to progressive right-sided heart failure. Clinicians need reliable ways to gauge severity and... Read moreUltrasound
view channelAI Robotic Ultrasound System Automates Echocardiography and Improves Consistency
Echocardiography, an ultrasound examination of the heart, is central to diagnosing and managing cardiovascular disease. Many services struggle with limited availability of skilled sonographers, variable... Read more
Whole Cross-Section Ultrasound System Enables Operator-Independent Imaging
Conventional ultrasound is central to bedside imaging but is limited by a narrow field of view and operator variability. Comprehensive cross-sectional assessment typically requires computed tomography... Read moreNuclear Medicine
view channel
Targeted PET Platform Guides Osteosarcoma Resection and Margin Verification
Osteosarcoma, an aggressive primary bone cancer that mainly affects children and adolescents, demands wide excision to prevent local recurrence. Surgeons must achieve negative margins while preserving... Read more
Portable PET System Enables Real-Time Bedside Guidance for Biopsies and Ablations
Interventional radiology procedures typically rely on ultrasound, X-ray fluoroscopy, or computed tomography for image guidance. These modalities visualize anatomy but offer limited molecular information,... Read moreGeneral/Advanced Imaging
view channelNew SPECT/CT Method Differentiates Inflammation from Fibrosis in Interstitial Lung Disease
Interstitial lung disease (ILD) encompasses more than 200 disorders that inflame or scar the lung interstitium and can lead to progressive respiratory failure. Determining whether active inflammation is... Read more
Whole-Body PET/CT Tracks Metabolic Changes After Bariatric Surgery
Obesity surgery improves weight and comorbidity profiles, yet clinicians lack tools to monitor organ-level metabolic recovery after the procedure. A clear view of systemic changes could refine follow-up... Read moreImaging IT
view channel
Interactive AI Tool Supports Explainable Lung Nodule Assessment
Lung cancer is a leading cause of cancer mortality, and timely characterization of pulmonary nodules on chest computed tomography (CT) is essential for directing care. Interpreting nodule morphology demands... Read more
Breast Imaging Software Enhances Visualization and Tissue Characterization in Challenging Cases
Breast imaging can be particularly challenging in cases involving small breasts or implants, where image reconstruction and tissue characterization may be limited. Clinicians also need reproducible analysis... Read more
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more







